Maintenance Therapy With Subcutaneous Bortezomib
A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF PROLONGED THERAPY WITH SC BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER SALVAGE WITH BORTEZOMIB-BASED THERAPY.
Sponsor: European Myeloma Network B.V.
This PHASE2 trial investigates Multiple Myeloma and is currently completed. European Myeloma Network B.V. leads this study, which shows 14 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2024 — Mar 2024 [monthly]
Completed PHASE2
▶ Show 9 earlier versions
-
Oct 2023 — Jan 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2022 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
-
Mar 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Unknown Status PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Unknown Status PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Sep 2018 — Dec 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Myeloma Network B.V.
- Fondazione EMN Italy Onlus
For direct contact, visit the study record on ClinicalTrials.gov .